Exforge Dosage/Direction for Use

The recommended dose of Exforge is one tablet per day.
Exforge may be administered in patients whose blood pressure is not adequately controlled with amlodipine or valsartan alone.
Exforge can be used with or without food.
Individual dose titration with the components (i.e. amlodipine and valsartan) is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered.
For convenience, patients receiving valsartan and amlodipine from separate tablets/capsules may be switched to Exforge containing the same component doses.
Renal impairment: There are no available clinical data in severely renally impaired patients. No dosage adjustment is required for patients with mild to moderate renal impairment. Monitoring of potassium levels and creatinine is advised in moderate renal impairment.
The concomitant use of Exforge with aliskiren is contraindicated in patients with renal impairment (GFR <60 ml/min/1.73 m²) (see Contraindications).
Diabetes mellitus: The concomitant use of Exforge with aliskiren is contraindicated in patients with diabetes mellitus (see Contraindications).
Hepatic impairment: Exforge is contraindicated in patients with severe hepatic impairment (see Contraindications).
Caution should be exercised when administering Exforge to patients with hepatic impairment or biliary obstructive disorders (see Precautions). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan. Amlodipine dosage recommendations have not been established in patients with mild to moderate hepatic impairment. When switching eligible hypertensive patients (see Indications) with hepatic impairment to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Elderly (age 65 years or over): In elderly patients, caution is required when increasing the dosage. When switching eligible elderly hypertensive patients (see Indications) to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Paediatric population: The safety and efficacy of Exforge in children aged below 18 years have not been established. No data are available.
Method of administration: Oral use.
It is recommended to take Exforge with some water.